Clinical Trial Update: A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Symbicort inhaler (budesonide/formoterol) with Formoterol Turbuhaler and placebo in patients with chronic obstructive pulmonary disease;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Formoterol Turbuhaler (formoterol)
• Symbicort (budesonide/formoterol)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease | Phase 3 | Status: COMPLETED